Former CFO of Auspex Pharmaceuticals
John Schmid has over 35 years of experience in financial and senior management in the biotech industry and has raised over $900 million in private and public equity as well debt financings as a Chief Financial Officer. He has taken two companies public as a CFO and over the past six years, he has been involved in six IPOs as an independent board member. He is currently a Board Member for AnaptysBio (Nasdaq: ANAB), Design Therapeutics (Nasdaq: DSGN), Poseida Therapeutics (Nasdaq: PSTX) and Xeris Pharmaceuticals (Nasdaq: XERS), as well as the SPAC, Helix Acquisition (Nasdaq: HLXA), and he serves as the Audit Chair for those companies as well. Mr. Schmid also serves on the Boards of Forge Therapeutics and Speak, Inc. Previously, he was the Chief Financial Officer of Auspex Pharmaceuticals which he joined in 2013 and took public in early 2014 before it was sold to Teva in 2015 for $3.5 billion. Prior to Auspex, Mr. Schmid co-founded Trius Therapeutics in 2004 where he served as CFO through its IPO and until its sale to Cubist Pharmaceuticals in 2013 for over $700 million. Before Trius, he was CFO of GeneFormatics and Endonetics (acquired by Medtronic) as well as an Associate with Idanta Partners, a venture capital firm, Vice President at HomeFed Bank and a Financial Analyst for Manufacturers Hanover (now part of J.P. Morgan) in New York. He is a past President and a past board member of the San Diego Venture Group. Mr. Schmid received a BA in Economics from Wesleyan University and an MBA from the University of San Diego.